Marker Therapeutics, Inc.
Sağlık
NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.
$0.9
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
WebsiteAnalysis (Turkish): MRKR Hissesi Caiz mi, Helal mi? Marker Therapeutics, Inc. Katılım Analizi